427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma.

Saved in:
Bibliographic Details
Title: 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
Authors: Moek, K L1 (AUTHOR), Fiedler, W M2 (AUTHOR), Einem, J C von3 (AUTHOR), Verheul, H M4 (AUTHOR), Seufferlein, T5 (AUTHOR), Groot, D J de1 (AUTHOR), Heinemann, V3 (AUTHOR), Kebenko, M2 (AUTHOR), Oordt, C W Menke-van der Houven van4 (AUTHOR), Ettrich, T J5 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy279.414